BioSpace News Archive

Promontory Therapeutics Inc. will present a poster on lead therapeutic candidate, PT-112, and its early molecular effects culminate in immunogenic cancer cell death (ICD), at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics. The AACR-NCI-EORTC “ENA Triple Conference” will be held from October 11-15, 2023 in Boston.

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced acceptance of five abstracts that will be presented at Obesity Week 2023, the annual meeting of The Obesity Society to be held in Dallas, Texas from October 14-17.

Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA ® (pembrolizumab) in Patients with Advanced Solid Tumors.

ATUM today announced an expanded partnership with Anagram Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases.

Inhibikase Therapeutics, Inc. today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Multiple System Atrophy (MSA).

Coherus BioSciences, Inc., announced that sales of CIMERLI® to retinal specialists have exceeded 100,000 doses since commercial launch on October 3, 2022.

Day Zero Diagnostics Inc. announced today the addition of Patricia (Trish) Simner , Ph.D., M.Sc., to its clinical advisory board.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s 7th Annual Meeting, which will take place October 19-20 in Washington, DC.

Kineta, Inc. announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock.

Akero Therapeutics, Inc. today announced publication in The Lancet Gastroenterology & Hepatology of results from the HARMONY Phase 2b trial in nonalcoholic steatohepatitis (NASH).